InVivo Therapeutics (NSDQ:NVIV) this week said that 2 neuro spinal scaffold trial patients who had reportedly improved have reverted to their original injury state. The company also released 1st quarter earnings which beat the Street, but still saw shares fall. The company said that a patient it had announced in January had improved from a complete AIS A […]
InVivo Therapeutics
Boston’s Brigham & Women’s joins InVivo Therapeutics Inspire study
InVivo Therapeutics (NSDQ:NVIV) said today Boston’s Brigham & Women’s Hospital joined the Inspire trial of the regenerative spinal scaffold it’s developing. The Cambridge, Mass.-based company is running a study of the neuro-spinal scaffold, an implant that’s designed to act as a physical substrate for nerve sprouting after acute spinal cord injuries. The 13th procedure in the trial, performed at […]
7 medtech stories we missed this week: April 7, 2017
New studies for umbilical cord allografts and tumor targeting were published this week while another company received European CE Marking. Here are some medtech stories we missed this week but thought were still worth mentioning. 1. AMNIOX touts new umbilical cord study AMNIOX Medical announced that it has published the results of 3 studies that demonstrate […]
Hook to step down as Integer CEO | Personnel Moves | March 31 , 2017
Integer Holdings (NYSE:ITGR) said this week that current CEO Thomas Hook has stepped down as the company’s president and CEO, effective immediately, with Joseph Dziedzic taking over as interim prez & CEO. Hook will stay on the Frisco, Texas-based company’s board until the company’s 2017 annual meeting of stockholders, but will not seek re-election. Dziedzic is currently a […]
InVivo enlists 1st Canadian site in cervical spinal scaffold study
InVivo Therapeutics (NSDQ:NVIV) said today that the Toronto Western Hospital will be the 1st Canadian site in the newly-launched study of its neuro-spinal scaffold in patients with acute, complete AIS A cervical spinal cord injuries. The neuro-spinal scaffold is designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for […]
Another InVivo spine injury patient converts
InVivo Therapeutics (NSDQ:NVIV) said today that a patient enrolled in January in its Inspire study has improved from a complete AIS A spinal cord injury to an incomplete AIS B spinal cord injury. This is the 7th patient from the 11-patient group to have an AIS grade improvement with at least 1-month of follow-up. 2 other […]
InVivo wins Health Canada nod for cervical neuro-spinal scaffold trial
InVivo Therapeutics (NSDQ:NVIV) said today it won Health Canada approval to initiate a clinical study of its neuro-spinal scaffold in patients with acute, complete AIS A cervical spinal cord injuries. The Cambridge, Mass.-based company said it is in late stage conversations with several site research ethics boards, and expects to announce the 1st Canadian site for the […]
InVivo submits 1st HDE module for neuro-spinal scaffold
InVivo Therapeutics (NSDQ:NVIV) said today it submitted its 1st nonclinical study module to the FDA as part of its humanitarian device exemption submission for its neuro-spinal scaffold. The neuro-spinal scaffold is designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting, the Cambridge, Mass.-based company said. The submission […]
InVivo Therapeutics enrolls 13th patient in neuro-spinal scaffold trial
InVivo Therapeutics (NSDQ:NVIV) said today that it enrolled a new patient in the Inspire study of its neuro-spinal scaffold, bringing the total number treated up to 13. The Cambridge, Mass.-based company’s neuro-spinal scaffold is designed to be surgically implanted following acute spinal cord injuries to act as a physical substrate for nerve sprouting. The procedure was […]
InVivo wins initial clearance to add UK trial sites to Inspire study
InVivo Therapeutics (NSDQ:NVIV) said today it won approval to commence clinical trials in the UK from the Medicines Healthcare Products Regulatory Agency. The Cambridge, Mass.-based company said it is in late-stage conversation with various clinical sites in the UK to join the Inspire study of its neuro-spinal scaffold, with a hopeful 1st opening “in the coming […]
InVivo steady on in-line Q4, FY2016 earnings report
Shares in InVivo Therapeutics (NSDQ:NVIV) rose slightly today after the medical device developer posted 4th quarter and full year 2016 earnings that mostly fell in line with consensus on Wall Street. The Cambridge, Mass.-based company posted losses of $5.4 million, or 17¢ per share for the 3 months ended December 31, with losses growing 14.8% while […]